"Claudins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A large family of transmembrane proteins found in TIGHT JUNCTIONS. They take part in the formation of paracellular barriers and pores that regulate paracellular permeability.
Descriptor ID |
D057167
|
MeSH Number(s) |
D12.776.543.940.200
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Claudins".
Below are MeSH descriptors whose meaning is more specific than "Claudins".
This graph shows the total number of publications written about "Claudins" by people in this website by year, and whether "Claudins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2005 | 0 | 1 | 1 |
2006 | 0 | 2 | 2 |
2008 | 0 | 2 | 2 |
2010 | 1 | 1 | 2 |
2011 | 0 | 1 | 1 |
2012 | 0 | 2 | 2 |
2014 | 2 | 0 | 2 |
2015 | 1 | 1 | 2 |
2016 | 2 | 0 | 2 |
2018 | 1 | 0 | 1 |
2019 | 1 | 0 | 1 |
2022 | 0 | 2 | 2 |
2023 | 0 | 3 | 3 |
2024 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Claudins" by people in Profiles.
-
Evidence to Date on the Therapeutic Potential of Zolbetuximab in Advanced Gastroesophageal Adenocarcinoma. Curr Oncol. 2024 Feb 01; 31(2):769-777.
-
MRCK as a Potential Target for Claudin-Low Subtype of Breast Cancer. Int J Biol Sci. 2024; 20(1):1-14.
-
Argininosuccinate lyase deficiency causes blood-brain barrier disruption via nitric oxide-mediated dysregulation of claudin expression. JCI Insight. 2023 09 08; 8(17).
-
Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023 08; 29(8):2133-2141.
-
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023 05 20; 401(10389):1655-1668.
-
Matrix metalloproteinase 7 contributes to intestinal barrier dysfunction by degrading tight junction protein Claudin-7. Front Immunol. 2022; 13:1020902.
-
Chemotherapy Coupled to Macrophage Inhibition Induces T-cell and B-cell Infiltration and Durable Regression in Triple-Negative Breast Cancer. Cancer Res. 2022 06 15; 82(12):2281-2297.
-
Claudin-18 expression in oesophagogastric adenocarcinomas: a tissue microarray study of 523 molecularly profiled cases. Br J Cancer. 2019 07; 121(3):257-263.
-
DPYSL3 modulates mitosis, migration, and epithelial-to-mesenchymal transition in claudin-low breast cancer. Proc Natl Acad Sci U S A. 2018 12 18; 115(51):E11978-E11987.
-
Sex-specific genetic predictors of Alzheimer's disease biomarkers. Acta Neuropathol. 2018 12; 136(6):857-872.